Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKesson
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
McKinsey
Farmers Insurance
Teva
Citi

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIAZOXIDE

« Back to Dashboard

Clinical Trials for Diazoxide

Trial ID Title Status Sponsor Phase Summary
NCT00004825 Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism Completed Children's Hospital of Philadelphia N/A OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00004825 Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism Completed FDA Office of Orphan Products Development N/A OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
NCT00131755 Efficacy of Diazoxide in Type 1 Diabetes Completed Grill, Valdemar, M.D. Phase 4 The purpose of this study is to find out if Diazoxide can partly retain insulin production in newly diagnosed type 1 diabetes patients.
NCT00151684 Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men Completed Rijnstate Hospital Phase 2 The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia. Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.
NCT00184821 Ischemic Injury and Ischemic Preconditioning in Diabetes Completed Dutch Diabetes Fund N/A In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise. The following hypotheses are tested: 1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers. 2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Diazoxide

Condition Name

Condition Name for Diazoxide
Intervention Trials
Hypertriglyceridemia 5
Hyperinsulinism 3
Prader-Willi Syndrome 3
Congenital Hyperinsulinism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Diazoxide
Intervention Trials
Hypoglycemia 7
Hyperinsulinism 6
Congenital Hyperinsulinism 5
Hypertriglyceridemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Diazoxide

Trials by Country

Trials by Country for Diazoxide
Location Trials
United States 30
Netherlands 3
France 2
Canada 2
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Diazoxide
Location Trials
California 5
New York 5
Colorado 2
Minnesota 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Diazoxide

Clinical Trial Phase

Clinical Trial Phase for Diazoxide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Diazoxide
Clinical Trial Phase Trials
Completed 16
Recruiting 8
Unknown status 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Diazoxide

Sponsor Name

Sponsor Name for Diazoxide
Sponsor Trials
Essentialis, Inc. 8
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 4
Albert Einstein College of Medicine, Inc. 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Diazoxide
Sponsor Trials
Other 26
Industry 14
NIH 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
Queensland Health
Baxter
Argus Health
Mallinckrodt
Farmers Insurance
Chubb
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.